Kerri Fitzgerald

DocwireNews

A study published in the&nbsp;Journal of Clinical Investigation&nbsp;found that&nbsp;men with&nbsp;defective mismatch repair&nbsp;(dMMR) prostate cancer had worse overall survival (OS).&nbsp;&nbsp;The researchers&nbsp;assessed&nbsp;127 biopsy specimens from 124 patients with advanced prostate cancer who underwent treatment at the Royal Marsden Hospital in London.&nbsp;Using polymerase chain reaction assay, they determined&nbsp;dMMR&nbsp;status&nbsp;based on&nbsp;either loss of mismatch repair protein expression or microsatellite instability&nbsp;(MSI).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
We've shown that prostate cancer with DNA repair defects (encompassing dMMR) have a very poor prognosis overall &ndash; similar is seen in breast and ovarian cancer with HR defects &ndash; do very poorly without DNA damaging treatment (but very well with) <a href="https://t.co/5GlDFJ9obK">https://t.co/5GlDFJ9obK</a>
&mdash; Dr Eileen Parkes (@eileen_parkes) <a href="https://twitter.com/eileen_parkes/status/1037609061699776512?ref_src=twsrc%5Etfw">September 6, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;Among the cohort,&nbsp;8.1% had&nbsp;dMMR&nbsp;cancers. The&nbsp;dMMR&nbsp;and a high degree of MSI&nbsp;defects are found most commonly in colorectal, endometrial, and gastrointestinal cancers&nbsp;and occur&nbsp;less commonly in other cancers, including&nbsp;prostate cancer.&nbsp;From&nbsp;the&nbsp;time of diagnosis, the median OS was 8.5 years&nbsp;among those with&nbsp;non-dMMR&nbsp;prostate cancers&nbsp;compared with&nbsp;4.1 years&nbsp;for those with&nbsp;dMMR&nbsp;prostate cancer (P=0.07). From the time of hormone therapy initiation,&nbsp;the&nbsp;median OS was 7.0 years for the&nbsp;non-dMMR&nbsp;group versus 3.8 years for the&nbsp;dMMR&nbsp;group (P=0.003).&nbsp;<a href="https://proddocwire.wpengine.com/hematology-oncology/annual-report-indicates-overall-cancer-mortality-continues-decline-except-for-prostate-cancer/">An annual&nbsp;report&nbsp;indicates that overall&nbsp;cancer&nbsp;mortality&nbsp;continues&nbsp;decline,&nbsp;except for&nbsp;prostate&nbsp;cancer.</a>&nbsp;<a href="https://proddocwire.wpengine.com/hematology-oncology/smoking-status-affects-prostate-cancer-survival/">Smoking status affects prostate cancer survival.</a>&nbsp;<a href="https://proddocwire.wpengine.com/hematology-oncology/cost-savings-observed-with-docetaxel-versus-abiraterone-acetate-for-prostate-cancer/">Cost savings were observed with docetaxel versus abiraterone acetate for prostate cancer.</a>&nbsp;Source:&nbsp;<a href="https://www.jci.org/articles/view/121924#B4">Journal of Clinical Investigation&nbsp;</a>

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Latest News

Study Identifies Specific Mutation Associated With Decreased Survival in Prostate Cancer

Oncology

A study published in the Journal of Clinical Investigation found that men with defective mismatch repair (dMMR) prostate cancer had worse overall survival (OS).   ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe